Rheumatoid Arthritis Therapeutics Market Growth Analysis and In-depth Analysis by Application, Region to 2022

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.

Browse Detail Report With TOC @ http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
 
The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-α inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-α inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-α inhibitors.

Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA. Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition.

Request A Sample copy of This Report @ http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022/request-sample

Scope

• What are the competitive advantages of the existing novel drugs?
• Which classes of novel drugs are most prominent in the pipeline?
• What is the potential for pipeline products to address unmet needs in the RA market?
• How do failure rates vary by stage of development, molecule type, and molecular target?
• How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
• Which markets make the most significant contribution to the current market size?
• What are the epidemiology trends in these markets?

Reasons to buy

1. Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
2. Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
3. Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
4. Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
5. Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017
 
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017
 
Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017

Psoriasis Drugs Market Estimation and Forecasts by Region to 2022

Psoriasis is a chronic, non-communicable, painful, disfiguring and disabling disease. This disease causes rapid build-up of skin cells. This disease can occur at any age, and is most common in the age group of 50-69 years. According to World Health Organization, the prevalence of psoriasis in different countries ranges between 0.09% and 11.4%. Treatment of this disease is based on controlling of its symptoms. Topical and systemic therapy drugs are used in combination, in order to combat this disease.

As per report "Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022", the global psoriasis drugs market is anticipated to witness a high growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market.

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-psoriasis-drugs-market
 
The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe.

Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs.

Request A Sample copy of This Report @ http://www.hexareports.com/report/global-psoriasis-drugs-market/request-sample
 
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global psoriasis drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global psoriasis drugs industry. The pipeline of psoriasis drugs have also been mentioned in the report.

The last section of the report discusses about the prominent players in global psoriasis drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global psoriasis drugs market.

Table Of Content

1. Analyst View
2. Research Methodology
3. Psoriasis: An Overview
4. Market Dynamics
5. Global Psoriasis Drugs Market Outlook 2022
6. Market Segmentation by Type of Drug Molecule
7. Market Segmentation by Route of Administration
8. Market Segmentation by Mechanism of Action
9. Market Segmentation by Geography
10. Trends & Developments
11. Mergers, Acquisitions & Collaborations
12. Pipeline Analysis
13. Porter's Five Forces Analysis
14. Key Players

Browse More Healthcare Related Market Research Reports:

Indian Influenza Market By Product Type (Vaxigrip, Influvac)-Forecast 2020 -
http://www.hexareports.com/report/indian-influenza-market-by-product-type-vaxigrip-influvac-forecast-2020
 
Immuno-Oncology Market Global Forecast to 2022 -
http://www.hexareports.com/report/immuno-oncology-market
 
Site-Specific Drug Delivery Market World Forecasts to 2022 -
http://www.hexareports.com/report/site-specific-drug-delivery-market

Pharmaceutical Lifecycle Management Market Size, Trends, Outlook and Growth Prospect Analysis by 2022

Pharmaceutical Lifecycle Management Strategies in 2017 provides a comprehensive assessment of product lifecycle (LCM) management strategies that are being implemented by pharmaceutical companies around the world. The pharmaceutical industry remains highly competitive and lucrative, and companies are investing significant time and resources into implementing strategies aimed at preserving the revenue streams of their products by extending patent life, delaying competition or slowing the pace of revenue loss following the end of market exclusivity.

The study, delivered in the form of an 82-slide PowerPoint presentation investigates a wide range of commercial, developmental, legal and regulatory strategies. This report format allows you to easily assemble high-quality presentations and research material to meet a variety of corporate requirements. Our research deep dives into the rationale for implementing LCM strategies, as well as the challenges, risks and commercial opportunities they represent.

Browse Detail Report With TOC @ http://www.hexareports.com/report/pharmaceutical-lifecycle-management-strategies-in-2017
 
Moreover, detailed case studies showcasing recent real-world examples of LCM strategies will enable understanding of the key factors that determined their success. Information leveraged from our robust industry-leading database also highlights strategies being implemented for products currently in development.

The pharmaceutical industry will continue to face a wide range of challenges in the coming years, including patent cliffs, declining productivity, intensifying levels of competition from generic and biosimilar manufacturers, low reimbursement levels and stricter regulatory policies. Careful LCM planning will continue to be a crucial element of the industry’s ability to answer these problems.

Request A Sample copy of This Report @ http://www.hexareports.com/report/pharmaceutical-lifecycle-management-strategies-in-2017/request-sample
 
It conducted extensive research to provide a comprehensive understanding of the LCM strategies being implemented by players in the pharmaceutical industry. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.

Scope

• What is driving the need for effective LCM strategies in the pharmaceutical industry?
• What are the most common LCM strategies being implemented?
• What are the business opportunities and commercial rewards arising from the implementation of LCM strategies?
• What are the key factors that impact the choice of LCM strategy?
• What strategies have Big Pharma companies implemented in recent years to preserve revenues and market share?

Key Reasons to Purchase

1. Gain insights into the rationale for implementing LCM strategies, alongside their key challenges, risks and potential benefits.
2. Understand the key challenges that the pharmaceutical industry has been facing in recent years
3. Assess real-world examples of successful strategies implemented in the past, and the key factors that determined their success.
4. Obtain information on strategies for products currently in development.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

Evolving Pharmaceutical Marketing Strategies: Digital as a Key Component of Multichannel Marketing -
http://www.hexareports.com/report/evolving-pharmaceutical-marketing-strategies
 
Strategic Trends in Private Equity and Venture Capital Funding for Healthcare -
http://www.hexareports.com/report/strategic-trends-in-private-equity-and-venture-capital-funding-for-healthcare
 
The Future of Generic Drugs and Strategies for Commercial Success -
http://www.hexareports.com/report/the-future-of-generic-drugs-and-strategies-for-commercial-success

Neurodegenerative Disorders Drug Market Analysis by Application, Region and Segment Forecast to 2022

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Browse Detail Report With TOC @ http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017
 
Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is lower, representing approximately 26% of the pipeline.

Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage. The report provides comprehensive information on the pipeline development landscape for is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage.

Request A Sample copy of This Report @ http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017/request-sample
 
This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

• Which companies are the most active within the pipeline for neurodegenerative disorders?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

1. Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
2. Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
3. Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
4. Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017
 
Colorectal Cancer - Heat Map and Analysis -
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis
 
Parkinson's Disease - Heat Map and Analysis -
http://www.hexareports.com/report/parkinsons-disease-heat-map-and-analysis

Immuno-Oncology Market Driver, Constraints, Key Events, Opportunities and Forecast 2017-2022

Immuno-oncology market has witnessed a high number of advancements. The competition between the players is intensifying. The biotechnology and pharmaceutical companies are striving to achieve first mover advantage by launching new and most effective therapies. This therapy is expected to be a game-changing approach to treating cancer.

The report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022" provides a detailed analysis of the current and future market scenario of the global Immuno-oncology market with a brief overview of the industry. The report also provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Immuno-oncology market.

Browse Detail Report With TOC @ http://www.hexareports.com/report/immuno-oncology-market
 
According to this edition of the report, the Immuno-oncology market is anticipated to hit billions of dollars within the next 5-10 years. The report also provides the sales of major marketed Immuno-oncology drugs.

On the basis of type of product, the global Immuno-oncology market has been segmented into major product classes including monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme prodrug therapy and radio immunotherapy). Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America was estimated to account for the largest share.

Request A Sample copy of This Report @ http://www.hexareports.com/report/immuno-oncology-market/request-sample
 
Primarily, the Immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

Moreover, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, we have provided information about the Immuno-oncology programs at various stages of clinical development. The study also provides a comprehensive overview of various aspects of the clinical trials in the Immuno-oncology market, such as phases, and product type. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The latter part of the report discusses some of the prominent players in the Immuno-oncology market. Some of the key players dominant in the market are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck among others. A brief business overview of each player has been provided, along with their product and pipeline portfolios and recent developments.

Overall, Immuno-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years; and thus the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Browse More Healthcare Related Market Research Reports:

Global Medical Implant Market Forecast till 2022 -
http://www.hexareports.com/report/global-medical-implant-market
 
Microfluidics Market World Forecasts to 2022 -
http://www.hexareports.com/report/microfluidics-market-analysis
 
Global Antibody Drug Conjugates Market Outlook 2022 -
http://www.hexareports.com/report/global-antibody-drug-conjugates-market

Breast Cancer Therapeutics Market Regional Consumption and Market Size Forecast by 2022

Breast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into two types: the human epidermal growth factor receptor (HER) 2-negative segment and the HER2-positive segment. HER2-positive breast cancer is aggressive and, historically, has had a worse overall survival than HER2-negative disease, which is considered less aggressive.

In HER2-negative breast cancer, a number of different factors can influence the choice of therapy that a patient receives, including the stage of the cancer, the hormonal receptor status of the cancer (ER-positive or -negative and PR-positive or -negative) and whether the patient is a BRCA-mutation carrier. Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no targeted therapy options being available. Chemotherapy is the mainstay of treatment in this setting. For HR-positive disease, endocrine therapies are the primary treatment.

Browse Detail Report With TOC @ http://www.hexareports.com/report/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022
 
Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies are expected to significantly improve survival outcomes in all lines of the disease. The introduction of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-negative, HR-positive breast cancer.

In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment plan for the disease, poor affordability, and patients continuing to rely on the use of chemotherapies in the later lines of treatment. It is important for drug companies to consider the evolving reimbursement landscape when determining pricing strategies across the Southeast Asian markets, because this will significantly impact the uptake of premium drugs.

Request A Sample copy of This Report @ http://www.hexareports.com/report/breast-cancer-therapeutics-in-southeast-asia-markets-to-2022/request-sample
 
Scope

• Which drugs are used as the standard treatment in each setting of the disease?
  What are the competitive advantages of the existing novel drugs?
• Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
• There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and
• Which molecular targets appear most frequently in the pipeline?
• There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?

Reasons to buy

1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
2. Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
3. Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
4. Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
5. Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
6. Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 -
http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
 
Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017
 
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017

Antibody Drug Conjugates Market Research Methodology and Cost Structure analysis 2017-2022

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Advancements in coupling monoclonal antibodies to cytotoxic drugs permit better control of drug pharmacokinetics, and significantly improve delivery to target tissue.

Potent novel anti-cancer drugs can now be used to target cancers, while minimizing the exposure of healthy tissue. The recent approvals of two potent ADCs - ADCETRIS and Kadcyla, followed by several Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in this industry.  According to the report entitled "Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022", the ADC market is poised to reach US$ 18.1 Billion by 2022.

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-antibody-drug-conjugates-market
 
In this report, there is in-depth market analysis of ADCETRIS and Kadcyla. The market potential of these ADCs is estimated considering that these are being tested in clinical trials for several cancer indications, besides the ones which have already been approved. The depicted ADCs are expected to show their complete market potential soon in the coming years. Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies.

The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, mode of action, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry's growth.

Request A Sample copy of This Report @ http://www.hexareports.com/report/global-antibody-drug-conjugates-market/request-sample
 
In the end, the report enlists some of the key players in the ADC market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Table Of Content

1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. ADC Market Outlook to 2022
5. ADC Pipeline Analysis
6. Drivers and Challenges
7. Major Potential ADCs in Pipeline
8. Trends and Developments
9. Strategic Collaborations in the ADC Industry
10. Competitive Assessment

Browse More Healthcare Related Market Research Reports:

Global Hepatocellular Carcinoma Drug Market Forecast to 2022 -
http://www.hexareports.com/report/global-hepatocellular-carcinoma-drug-sales
 
Global Double Barreled Antibodies Drug Market Forecasts 2022 -
http://www.hexareports.com/report/global-double-barreled-antibodies-drug-sales-blincyto-removab-pipeline-analysis
 
Global Cartilage Repair and Regeneration Market by Application Outlook 2022 -
http://www.hexareports.com/report/global-cartilage-repair-and-regeneration-market